FDA approves Johnson & Johnson’s nasal spray for depression

J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
Safety and Feasibility of Intranasal Ketamine in Depression Treatment
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study,” published in the January 2025 issue of Psychiatry by Halpape et al.
Ketamine's Potential To Treat Depression Beautifully Shown In Struggling Zebrafish
Ketamine’s promising potential to ease depression is one of the reasons why its use has recently skyrocketed in the US and elsewhere. However, bear in mind that the science isn’t fully settled and, like any prescription drug, it should be used with caution and under professional supervision.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.
J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval addresses the need for new options for treatment-resistant depression,
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression,
Johnson & Johnson Secures FDA Approval For Nasal Spray as Depression Monotherapy
Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration approved nasal spray Spravato as the first-ever stand-alone therapy for major depressive disorder. The product, which targets the glutamate neurotransmitter in the brain,
Research indicates recreational ketamine use is on the rise
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
Medscape16h
Ketamine-Induced Uropathy: What Urologists Need to Know
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
US Weekly on MSN5d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, More
Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
What We Know About Musk's Ketamine Use
Musk himself has said he uses the drug to treat depression, and he's frequently posted about it on X generally over the years ...
Inquirer on MSN1d
Controlled drug Ketamine a lifeline for patients with severe depression in S’pore
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
US FDA approves standalone use of J&J’s ketamine-derived depression treatment
The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.
Psychology Today3d
New Strategies for Treatment-Resistant Depression
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
Ketamine Healing Clinic of Los Angeles and Orange County Honored as 2025 Top Patient Rated Doctor by Find Local Doctors
Dr. David Mahjoubi, a highly respected board-certified anesthesiologist and the founder of Ketamine Healing Clinic of Los Angeles and OC, has been recognized as a 2025 Top Patient Rated Doctor by Find ...